Advertisement
Screener

Lineage Cell Therapeutics, Inc. (LCTX) Deferred Costs

2.8 / 5 stars · 68/120 Roast Me

Lineage Cell Therapeutics, Inc. Deferred Costs

Lineage Cell Therapeutics, Inc. (LCTX) had Deferred Costs of $470.00 thousand as of 2015-12-31, per its 10-K filed 2016-03-15.

Discontinued › Balance Sheet › Assets

us-gaap:DeferredCostsCurrentAndNoncurrent · last filed 2016-03-15

  • 2015-12-31: Deferred Costs $470.00K.
  • 2015-06-30: Deferred Costs $406.00K.
  • 2015-03-31: Deferred Costs $418.96K.
  • 2014-12-31: Deferred Costs $446.33K.
Period endDeferred Costs
2015-12-31$470.00K
10-K · filed 2016-03-15
2015-06-30$406.00K
10-Q · filed 2015-08-10
2015-03-31$418.96K
10-Q · filed 2015-05-08
2014-12-31$446.33K
10-K · filed 2015-03-11
2014-03-31$528.46K
10-Q · filed 2014-05-12
2013-12-31$555.83K
10-K · filed 2014-03-17
2013-09-30$566.71K
10-Q · filed 2013-11-12
2013-06-30$594.08K
10-Q · filed 2013-08-09
2013-03-31$621.46K
10-Q · filed 2013-05-10
2012-12-31$648.83K
10-K · filed 2013-03-18

Similar stocks

Stock NameCountryMarket CapPE Ratio
Aligos Therapeutics, Inc. (ALGS)United States$0.238B-0.47
SUTRO BIOPHARMA, INC. (STRO)United States$0.260B-3.05
Protalix BioTherapeutics, Inc. (PLX)$0.221B9.87
ANAVEX LIFE SCIENCES CORP. (AVXL)United States$0.218B-18.37
Alector, Inc. (ALEC)United States$0.213B-1.90
Invivyd, Inc. (IVVD)United States$0.270B-2.42
PALISADE BIO, INC. (PALI)United States$0.275B-11.41
Compass Therapeutics, Inc. (CMPX)United States$0.204B-5.35
Lexeo Therapeutics, Inc. (LXEO)United States$0.278B-4.19
FATE THERAPEUTICS INC (FATE)United States$0.280B-2.51